Conference Coverage

Adalimumab strikes out for aortic inflammation in psoriasis

Publish date: June 27, 2018

 

REPORTING FROM IID 2018

The work was funded by the National Institutes of Health and AbbVie, adalimumab’s maker. Among many industry ties, Dr. Gelfand is a consultant for Janssen, maker of ustekinumab, and receives research grants from Janssen and AbbVie.

SOURCE: Gelfand JM et al. IID 2018, Abstract 393.

Pages

Recommended Reading

New PsA questionnaire fails to beat existing early screening methods
MDedge Dermatology
How to avoid severe diarrhea from apremilast
MDedge Dermatology
Surgical excision essential in severe hidradenitis suppurativa
MDedge Dermatology
Is PASI 100 the new benchmark in psoriasis?
MDedge Dermatology
Psoriasis duration reflects cardiovascular event risk
MDedge Dermatology
Hidradenitis suppurativa packs mighty QOL impact
MDedge Dermatology
Secukinumab Emerges as a Rapidly Effective Therapy for Pityriasis Rubra Pilaris
MDedge Dermatology
Topical corticosteroid-retinoid combination effective in moderate to severe psoriasis
MDedge Dermatology
CBC values linked to CVD risk in psoriasis
MDedge Dermatology
Psoriasis therapy with biologics not linked to increased cancer risk
MDedge Dermatology